ARVN
Price
$7.55
Change
-$0.25 (-3.21%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
551.45M
34 days until earnings call
GMAB
Price
$20.50
Change
-$0.23 (-1.11%)
Updated
Jun 27 closing price
Capitalization
12.76B
40 days until earnings call
Interact to see
Advertisement

ARVN vs GMAB

Header iconARVN vs GMAB Comparison
Open Charts ARVN vs GMABBanner chart's image
Arvinas
Price$7.55
Change-$0.25 (-3.21%)
Volume$25.27K
Capitalization551.45M
Genmab A/S ADS
Price$20.50
Change-$0.23 (-1.11%)
Volume$727.65K
Capitalization12.76B
ARVN vs GMAB Comparison Chart in %
Loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARVN vs. GMAB commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and GMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (ARVN: $7.55 vs. GMAB: $20.50)
Brand notoriety: ARVN and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 88% vs. GMAB: 49%
Market capitalization -- ARVN: $551.45M vs. GMAB: $12.76B
ARVN [@Biotechnology] is valued at $551.45M. GMAB’s [@Biotechnology] market capitalization is $12.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, GMAB is a better buy in the long-term than ARVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 6 TA indicator(s) are bullish while GMAB’s TA Score has 4 bullish TA indicator(s).

  • ARVN’s TA Score: 6 bullish, 3 bearish.
  • GMAB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARVN is a better buy in the short-term than GMAB.

Price Growth

ARVN (@Biotechnology) experienced а +1.55% price change this week, while GMAB (@Biotechnology) price change was -3.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

ARVN is expected to report earnings on Jul 31, 2025.

GMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($12.8B) has a higher market cap than ARVN($551M). GMAB YTD gains are higher at: -1.773 vs. ARVN (-60.589). GMAB has higher annual earnings (EBITDA): 1.35B vs. ARVN (-89.3M). GMAB has more cash in the bank: 3.23B vs. ARVN (954M). ARVN has less debt than GMAB: ARVN (10.5M) vs GMAB (143M). GMAB has higher revenues than ARVN: GMAB (3.12B) vs ARVN (427M).
ARVNGMABARVN / GMAB
Capitalization551M12.8B4%
EBITDA-89.3M1.35B-7%
Gain YTD-60.589-1.7733,418%
P/E RatioN/A12.03-
Revenue427M3.12B14%
Total Cash954M3.23B30%
Total Debt10.5M143M7%
FUNDAMENTALS RATINGS
ARVN vs GMAB: Fundamental Ratings
ARVN
GMAB
OUTLOOK RATING
1..100
6569
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8642
PRICE GROWTH RATING
1..100
6460
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (17) in the Biotechnology industry is somewhat better than the same rating for GMAB (59) in the null industry. This means that ARVN’s stock grew somewhat faster than GMAB’s over the last 12 months.

ARVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that ARVN’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (42) in the null industry is somewhat better than the same rating for ARVN (86) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than ARVN’s over the last 12 months.

GMAB's Price Growth Rating (60) in the null industry is in the same range as ARVN (64) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.

GMAB's P/E Growth Rating (93) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNGMAB
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 1 day ago
54%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 1 day ago
69%
MACD
ODDS (%)
Bullish Trend 5 days ago
79%
Bearish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 18 days ago
62%
Declines
ODDS (%)
Bearish Trend 5 days ago
82%
Bearish Trend 5 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 1 day ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WBALX16.88N/A
N/A
Weitz Conservative Allocation-Inv Cl
LEVOX11.79N/A
N/A
Lazard US Equity Concentrated Open
TWQIX15.52N/A
N/A
Transamerica Large Cap Value I
GLIFX17.88N/A
N/A
Lazard Global Listed Infrastructure Inst
TQSAX23.01N/A
N/A
T. Rowe Price Integrated US SMCC Eq Adv

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
-3.14%
AXON - ARVN
46%
Loosely correlated
+1.82%
VCYT - ARVN
46%
Loosely correlated
+2.13%
ERAS - ARVN
40%
Loosely correlated
+1.98%
ATXS - ARVN
40%
Loosely correlated
+2.94%
SRPT - ARVN
40%
Loosely correlated
-0.81%
More